Maternal folate supplementation and CBT 3
Maternal folate supplementation and CBT
5
This study provides evidence of a specific protective effect of prenatal folic acid supplementation against the risk of CBT that is not attributable to the actions of the other micronutrients (4) . These findings have not been replicated in subsequent ALL studies, although we found weak evidence of a protective association with folic acid use before pregnancy in our national Australian case-control study (5) . Protective effects of micronutrient supplementation before and during pregnancy against childhood cancers are biologically plausible.
In particular, folate and other B-vitamins are crucial in maintaining genomic stability through their intimate involvement in methylation and the synthesis and repair of DNA (6, 7) . With respect to CBT specifically, folate requirements are considerable as the developing fetus's neural crest and brain cells undergo rapid division. Thus, maternal folate insufficiency may disrupt these processes and predispose CNS cells to increased rates of DNA damage which, if unrepaired or misrepaired, can lead to mutation and malignant transformation (8) .
Previous studies of CBT have generally examined associations with use of vitamins as a group; four reported a protective effect (9) (10) (11) (12) , and a 2007 meta-analysis of multivitamin use before or early in pregnancy reported a summary odds ratio of 0.73 (95% confidence interval (CI) 0.60, 0.88) (13) . Recently, however, a German case-control study found no association with maternal use of vitamins, folate or iron supplements during pregnancy (14) ; a Swedish cohort study reported no association with vitamin use, but a weak inverse association with folic acid before In our study, the largest conducted to date, detailed information was collected about dose and timing of maternal use of specific micronutrient supplements, including folic acid, iron and vitamins A, B6, B12 and C, at specific times before and during pregnancy. Here we present the results of our study and seek to distinguish possible effects of folic acid from those of other vitamins.
MATERIALS AND METHODS
The Australian Study of Childhood Brain Tumours (Aus-CBT) was a national population-based Identical recruitment methods, described elsewhere (5, (17) (18) (19) , were used in both studies. Aus-CBT was approved by the Human Research Ethics Committees at all participating hospitals.
Mailed questionnaires were used to obtain medical and residential histories, demographic characteristics and exposure data, including whether mothers took 'folate supplements' (yes or no) in the month before the index pregnancy (pre-pregnancy), during trimester 1 and during trimesters 2/3. Mothers were also mailed food frequency questionnaires (FFQs), which included the open- (20) .
Statistical analysis
Unconditional logistic regression was used to estimate odds ratios (ORs) for the association between folic acid use and CBT risk, with 'no folic acid before or during pregnancy' as the reference category. Data from the FFQ were also grouped into categories of folic acid use with and without iron, with the reference category 'no folic acid or iron' before or during pregnancy.
These reference categories were used to avoid 'contamination' by women who had used supplements in a different time period. Folic acid dose was analyzed using both categorical and continuous methods. ORs were also estimated for use of vitamins B6 or B12 (they were almost always taken together), C, A, 'any' vitamins, and use of folic acid without any of these vitamins or iron. Dietary folate intake was excluded from our analysis because supplementation with folic acid has a much greater effect than dietary intake on folate status (21) , and folic acid supplementation was the primary focus of this analysis.
All analyses included the frequency matching variables age, sex and State of residence, and variables that met the classical definition of confounding: they were associated with case/control status and folic acid use among control mothers. Variables included on this basis were ethnicity, (17) . In accordance with our frequency-matching quotas, 1,467 of these families were recruited to the study. Mothers of 1,346 controls (92% of recruited) provided information about folic acid use, 17 provided only demographic information, and another 104 recruited families provided no data. Detailed data on dose and use of other vitamins were provided by 867 (59.1%) control mothers.
Demographic and other characteristics of cases and controls were similar, with some exceptions (Table 1) When characteristics of case and control mothers who completed a FFQ were compared, the distributions were similar to those for all participants shown in Table 1 and as described above for ISRD, except that a higher proportion of control than case mothers had a tertiary education (48.8% vs 40.7%) (data not shown in tables).
The ORs for the association between risk of CBT and maternal use of supplements containing folic acid before or during pregnancy were all below unity for both the exposure questionnaire and FFQ ( Table 2 ). The lowest ORs were for pre-pregnancy use -OR 0.65 (95% CI: 0.43, 0.96) (ascertained by exposure questionnaire) and OR 0.68 (95% CI 0.46, 1.00) (ascertained by FFQ).
ORs for use in Trimester 1 and in Trimesters 2/3 were somewhat closer to the null. The FFQ OR for folic acid use during Trimester 1 (with or without ongoing use into later pregnancy) but not pre-pregnancy was somewhat higher at 0.84 (95% CI 0.58, 1.23) (not shown in tables). ORs for use pre-pregnancy but not in Trimester 1 could not be calculated, since all but 3 case and 13 control mothers who took folic acid before pregnancy also took it in Trimester 1. Use of a less stringent reference group ("no folic acid in the same time period") allowed inclusion of many more subjects, particularly for the pre-pregnancy period, but did not materially alter the effect estimates (data not shown). There was evidence of a dose-response relationship for folic acid supplements taken pre-pregnancy and in Trimester 1 (linear trend p=0.01 and 0.03 respectively) and, to a lesser extent, in Trimesters 2 and 3 (p=0.08) ( Table 2) . When children from multiple births or with birth defects were excluded, the results did not change (data not shown); they were therefore included in all analyses.
Associations between risk of CBT and use of folic acid in combination with iron or other vitamins, and use of iron and vitamins B6 or B12, C and A individually, were analyzed in mothers who completed the FFQ (327 case and 867 control mothers). The ORs for combinations of folic acid and iron taken before or during pregnancy were all below unity ( Table 3 ). The lowest OR was for folic acid taken without iron before pregnancy: 0.56 (95% CI 0.35, 0.89). There was little evidence of any association between CBT and use of iron or vitamins B6 or B12, C or A in any time period (Table 3 ). The relatively low numbers in these analyses precluded mutual adjustment, but adjustment for folic acid use did not alter the results (not shown). Maternal use of 'any vitamins' before pregnancy was inversely associated with CBT risk, and there was evidence of a similar albeit weaker association for use during pregnancy ( Table 3 ). Note that all but 3 control and 13 case mothers who took vitamins before pregnancy also took folic acid. Finally, we estimated the ORs for use of folic acid without iron or vitamins B6, B12, C or A. The OR for prepregnancy use was 0.55 (95% CI 0.32, 0.93), while there was little evidence of a similar association with use during pregnancy. This analysis, though, was based on only about a third of all folic acid users, as most women who took folic acid took preparations that contained at least one of the other micronutrients.
We also investigated use of folic acid and any vitamin supplements among the two largest CBT subtypes -low-grade gliomas and medulloblastoma/primitive neuroectodermal tumors (PNET).
The results were similar to the overall results but there was stronger evidence for an inverse trend with increasing folic acid intake for low grade gliomas than for meduloblastoma/PNET (Table 4) .
The other brain tumor sub-groups were too small to allow separate analyses. We observed an inverse association between maternal use of folic acid before pregnancy and CBT, with evidence of an inverse dose-response. Similar but weaker associations were observed for folic acid use during pregnancy suggesting that pre-pregnancy might be a more biologically relevant time period. The findings were similar for low grade gliomas and medulloblastoma/PNET, the commonest types of CBT.
The only previous study to investigate maternal folic acid use before pregnancy reported an OR of 0.34 (95% CI 0.10, 1.06) for CBT with maternal intake of ≥ 400μg folic acid per day (16) . A reduction in risk was also observed for use in the first 36 days of gestation, OR=0.57 (95% CI 0.33, 0.99), but not 'before or during pregnancy', OR=0.94 (95% CI 0.78, 1.14). However, the control group for this study comprised children with mesodermal tumors (e.g. leukemia, lymphoma, kidney cancer). Given the evidence of associations between folic acid and these other tumors (14, 22) , interpretation of these results is not straightforward. One previous study investigated any vitamin use before pregnancy and risk of CBT and reported an OR of 1.2 (95% CI 0.8, 1.8) (12) . Thus, our findings add substantially to the evidence that folic acid use before pregnancy reduces risk of CBT, and suggest that the association is specific to folic acid since its association appeared to be independent of any effect of iron, and the ORs for iron and vitamins B6, B12, C and A were all close to unity. The evidence of an inverse dose-response relationship also supports an association specific to folic acid. Aus-CBT was a population-based study designed to address specific hypotheses, including that maternal use of folic acid protects against CBT. Therefore, more comprehensive data were collected about the dose and timing of use of folic acid and other vitamins than in previous studies. Almost 78% of eligible cases were invited to participate by the treating clinician and 66% of invited parents consented, resulting in an overall participation fraction of 51%. Except for age and sex, where the distributions were similar to participating cases, information about eligible cases who did not participate was unavailable, so we were unable to determine whether our cases were representative of all eligible cases with respect to potential risk factors. Control families were recruited by national RDD using state-of-the-art methods and, according to the most recent data available (26, 27) , approximately 90% of Australian households had a landline telephone connection during the recruitment period. Therefore, residences contacted are likely to be representative of the wider population. Participation among eligible control families was 62% and, although no individual information was available for those who declined, area-based SES scores were higher among participating controls than among the wider Australian population. Thus, as periconceptional folic acid use is known to be positively associated with SES (28), the inverse associations we observed may have been overestimated. However, importantly, participating cases and controls had very similar SES distributions, and about 90% of both case and control mothers provided information about whether folic acid was used. Thus, it is unlikely that our findings can be entirely attributed to selection bias.
While 87% of case mothers completed the FFQ (requesting detailed use of any supplements), only 59% of control mothers did so. However, although a higher proportion of this group of control mothers had a university or college education, household income and area-based SES measures were similar among cases and controls in this subset. Maternal education was considered a priori to be a potential confounder and was included in all analyses. Moreover, the results of the analysis of folic acid use from the exposure questionnaire and the open-ended FFQ questions were similar.
Due to the dependence on self-reported data, there is likely to have been error in exposure measurement, particularly as the index pregnancy was 15 years earlier for some mothers.
However, the recall period was five years or less for almost 60% of mothers, and the percentages The possibility that mothers of cases ruminate about the causes of their child's cancer and recall exposure more completely than control mothers is inherent in case-control studies and may introduce recall bias. However, case mothers' enhanced recall of a potentially protective exposure would not be expected to produce an inverse association; but it might weaken one. There is evidence of this weakening in our data. Case and control mothers' reporting of periconceptional folic acid use increased with the index child's birth year, which ranged from 1990 to 2010. This increase was greater in control mothers (14.7% to 50.3%) than case mothers (16.1% to 41.0%).
Thus, ORs for CBT with maternal folic acid use in children born earlier were close to unity, while these ORs were below unity for children born more recently. We suggest that this trend in ORs is due to more complete (or possibly exaggerated) recall by case than control mothers of folic acid use further in the past. As recruitment occurred over five years while the children were born over a much longer period, it is unlikely to be due to increasing SES of controls over the recruitment period. Moreover, we have shown that although control participation fractions have decreased over time in Australia, this fall has not been accompanied by a commensurate increase in SES (31) . Mandatory fortification of bread-making flour in Australia began in September 2009 and, although fortification was permitted before this date, most millers did not implement fortification until the end of August 2009 at the earliest. Only 1 case and 4 controls were born after that time; therefore, it is unlikely to have affected our findings.
A reduced risk of CBT associated with maternal folic acid supplementation is biologically plausible through known mechanisms, and a stronger inverse association with use before pregnancy is consistent with the fact that ovarian stimulation and follicular development are subject to the availability of folate (32) . Low levels of folate are associated with increased 
oxidative stress (33) and inappropriate DNA methylation (34), thereby potentiating disease development. Some CNS tumors involve mutations or aberrant DNA methylation in signaling pathway genes, activation of oncogenes or inactivation of tumor suppressor genes (2) -all of which may result from folate insufficiency. Histone lysine methylation, in which folate would be involved as a methyl donor, may play a part in the pathogenesis of medulloblastoma (35) . The fact that polymorphisms in folate pathway genes causing altered enzyme kinetics are associated with an increased risk of risk of brain tumors in children (36) and adults (37) adds to the biological plausibility that folate is involved. Interestingly, inverse associations have been reported between folic acid or multivitamin use and other solid tumors in children (14, 22, 38, 39) , but the responsible micronutrients have not been identified.
Our study of maternal folic acid supplementation and risk of CBT is the largest and most comprehensive to date. It provides evidence of an inverse association of CBT with folic acid use before pregnancy and, to a lesser extent, during pregnancy. Similar associations were observed with multivitamin supplements, but there was little evidence that other vitamins or iron, with which folic acid supplementation is strongly associated, might explain the inverse association with folic acid. Limited earlier literature provides some support for these findings. We conclude that folic acid supplements before and in early pregnancy may protect against CBT. Potential underlying mechanisms should be further investigated, particularly for individual CBT subtypes as the mechanisms may well differ.
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